Modality
Vaccine
MOA
PI3Ki
Target
FXIa
Pathway
PD-1/PD-L1
Heart FailurePompeParkinson's
Development Pipeline
Preclinical
Aug 2017
→ Oct 2031
PreclinicalCurrent
NCT03374589
204 pts·Heart Failure
2017-08→TBD·Active
NCT07927603
2,691 pts·Heart Failure
2017-08→2031-10·Not yet recruiting
2,895 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-275.6y awayInterim· Heart Failure
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Active
Preclinical
Not yet…
Catalysts
Interim
2031-10-27 · 5.6y away
Heart Failure
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03374589 | Preclinical | Heart Failure | Active | 204 | DOR |
| NCT07927603 | Preclinical | Heart Failure | Not yet recr... | 2691 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 |